LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra Test
LumiraDx submits a traditional 510 Dual Submission for LumiraDx SARS-CoV-2 Ag Ultra with CLIA Waiver for the commercial distribution at point of care of the LumiraDx Platform, including the LumiraDx...
Source: marketscreener.com